NPS Pharmaceuticals Submits Biologic License Application to the U.S. Food and Drug Administration for Natpara® in Hypoparathyroidism

25-10-2013 Business Wire HealthComments (0)

NatparaNPS PharmaceuticalsPharmaceutical

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has submitted its Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Natpara® (recombinant human parathyroid hormone 1-84, rhPTH(1-84)). Natpara is a bioengineered replacement for endogenous parathyroid hormone (PTH) that NP

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top